IGFBP3 and colorectal carcinoma: Nevertheless it is important to point out that although IGFBP3 methylation status emerged as the only independent factor that predicted poor DFS probability among stage II CRC patients, additional independent clinical studies are required to prove that IGFBP3 methylation levels in CRC could represent a potential routine test for prognostication of CRC patients, and in improving the management of patients with localized disease in combination with current clinicopathological and molecular tools.